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Abstract: Dendritic cells play a fundamental role in the antitumor immunity cycle, and the loss of
their antigen-presenting function is a recognized mechanism of tumor evasion. We have recently
demonstrated the effect of exosomes extracted from serum of patients with acute myeloid leukemia
as important inducers of dendritic cell immunotolerance, and several other works have recently
demonstrated the effects of these nanoparticles on immunity to other tumor types as well. The aim of
this review was to highlight the recent findings on the effects of tumor exosomes on dendritic cell
functions, the mechanisms by which they can lead to tumor evasion, and their manipulation as a
possible strategy in cancer treatment.
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1. Introduction
In recent years, there has been a growing interest in the role of non-neoplastic cells infiltrating the
tumor environment, such as mesenchymal cells, endothelial cells, and immune system components. It
is becoming increasingly evident that the biology of tumors, including their proliferation, invasion,
and spread capabilities, depend largely on the support or repression of these other cell types, especially
the cells of the immune system [1].
Tumor cells use various mechanisms to escape the immune system that may directly impact
the prognosis of cancer patients and their response to currently available therapies. These actions
include features such as attracting immunosuppressive cell populations to infiltrate the tumor
microenvironment, as well as modulating normal immune cells to a more permissive and tolerant
phenotype polarized for tumor growth and spread [2]. Furthermore, recent studies have shown the
possibility of altering tumor growth and preventing its escape mechanisms by blocking or eliminating
these dysfunctional immune cells, or by reprogramming their functions to a cytotoxic state [3].
It is currently known that tumor escape mechanisms depend largely on soluble factors acting
on intercellular communication, such as the secretion of cytokines and growth factors. In this
context, numerous recent studies have demonstrated an important role of extracellular vesicles
(mainly exosomes) released in the tumor microenvironment as important modulators of the immune
system [4,5]. Therefore, the aim of this review was to depict the effects of exosomes specifically on
the performance of dendritic cells (DCs) present in the tumor microenvironment, as well as their
role in tumor evasion and treatment response. In addition, we addressed the promising therapeutic
approaches involving both the effect of exosomes on the priming of dendritic cells and the paracrine
effects of exosomes released by these important antigen-presenting cells themselves.
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2. Dendritic Cells Functionality in Intratumoral Immune Infiltrate
The discovery of dendritic cells in 1972 was considered a major milestone in understanding
the functioning of the immune system and, later, in grasping the immunology of tumors [6]. Their
specialized capabilities for antigen capture, processing, and presentation have been progressively
described and can be seen in detail in Figure 1. Dendritic cells present a wide tissue distribution, acting
as a surveillance system that connects the innate and adaptive immune systems. They are generated
through bone marrow precursors and are classified into four general groups: conventional DCs (cDC),
plasmocytoid DCs (pDC), monocyte derived DCs, and Langerhans cells. cDCs are further classified
according to their tissue location, surface markers, and more recently by the expression of specific
transcription factors as well [7].
Cells 2020, 9, x FOR PEER REVIEW 2 of 12 
 
2. Dendritic Cells Functionality in Intratumoral Immune Infiltrate 
The discovery of dendritic cells in 1972 was considered a major milestone in understanding the 
functioning of the immune system and, later, in grasping the immunology of tumors. [6] Their 
specialized capabilities for antigen capture, processing, and presentation have been progressively 
described and can be seen in detail in Figure 1. Dendritic cells present a wide tissue distribution, 
acting as a surveillance system that connects the innate and adaptive immune systems. They are 
generated through bone marrow precursors and are classified into four general groups: conventional 
DCs (cDC), plasmocytoid DCs (pDC), monocyte derived DCs, and Langerhans cells. cDCs are further 
classified according to their tissue location, surface markers, and more recently by the expression of 
specific transcription factors as well. [7] 
 
Figure 1. Interplay between dendritic cells and exosomes in the antitumor immunity cycle. Tumor 
derived exosomes (TEX) are internalized by dendritic cells (DC) resulting in impaired lymphocyte 
activation. Exosomes released from dendritic cells after contact with tumor antigens (DEX) potentiate 
NK cytotoxicity. DC: dendritic cells; NK: natural killer cells; CTL: cytotoxic T lymphocytes; DEX: 
dendritic cell derived exosomes; TEX: tumor derived exosomes; MHCI: major histocompatibility 
complex I. 
The elemental function of DCs is to prime and activate naive T cells for an adaptive immune 
response. In their immature form, they are avidly capable of antigen capture and are characterized 
by low expression of major histocompatibility complex (MHC) molecules and co-stimulatory 
molecules (such as CD80 and CD86). [8] After recognition of molecular patterns associated with 
pathogens or other antigenic signals (including the presence of tumor cells), DCs undergo a 
maturation process with increased expression of MHC and co-stimulators on their surface, as well as 
releasing cytokines, which are essential for T lymphocyte activation. [9,10] 
In most tumors, the onset of the T cell-mediated cytotoxic immune response also begins with the 
presentation of disease-related antigens by the dendritic cells to the cytotoxic CD8+ and helper CD4+ 
T lymphocytes through molecules of the MHC class I and II, respectively. Following stimulation, 
naïve CD4+ T cells can be polarized into type 1 helper T cells (TH1), which in turn support the 
generation and proliferation of antigen-specific cytotoxic T lymphocytes. These lymphocytes 
(through their specific T cell receptor) are capable of recognizing tumor cells that exhibit the specific 
antigens to which they had been stimulated. Then follows the cytotoxic attack, for which these 
lymphocytes have different possible tools, such as cell death-associated receptor ligands (such as 
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tools, such as cell death-associated receptor ligands (such as FasL) or cytolytic proteins released from
intracytoplasmic granules (such as granzyme B and perforin) [11,12].
However, tumor clones may develop abilities to escape this defense system and proliferate
leading to a new manifest disease or relapse. Tumor evasion can occur by several mechanisms,
such as decreased immune recognition through the tumor cells’ production of antigens with lower
immunogenicity, reduced expression of MHC molecules leading to lower antigen presentation capacity,
and failure to activate effector cytotoxic cells. In addition, tumor cells can stimulate the development
of an immunosuppressive tumor microenvironment through cytokine release and proliferation of
regulatory T lymphocytes (Tregs) [13].
Precisely because of their inherent plasticity, DCs can become prone to the effects of the
immunosuppressive tumor microenvironment: tumor cells can suppress the functions of DCs by
polarizing them into an immunotolerant phenotype or by recruiting precursors of immunosuppressive
DCs. Several mechanisms have been described to explain these changes, including the effect of various
cytokines, such as IL-6 and IL-10, growth factors, and metabolic and oxidative changes [14,15]. More
recently, the role of tumor-derived microvesicles has also begun to be unraveled in this process.
3. Tumor Immune Evasion: Role of Exosomes
3.1. Exosomes in Intercellular Communication: Effects on Immune Response
Exosomes are small vesicles measuring approximately 30 to 150 nm in size secreted by different
cell types, which have recently received great attention for their possible role as biomarkers in various
pathological conditions [16]. Despite having been previously cited as mere cell debris, recent studies
have shown an active role of exosomes in intercellular communication by transporting proteins, RNA,
and microRNAs that can significantly alter the function of target cells [17,18]. The exosomes are now
known to correspond to intraluminal vesicles of endosomal multivesicular bodies (MVBs), formed
after endosome invagination and released into the extracellular space by fusion of the MVBs with the
plasma membrane. Due to their cellular origin, these particles contain endosomal pathway-specific
marker proteins such as tetraspanins (CD63, CD9, and CD81) and heat shock proteins (HSP70) [19].
The exosomes were first visualized in medium collected from reticulocyte cultures [20]; since
then, several cell types have been identified as exosome sources, such as hematopoietic cells, epithelial
cells, neurons, and adipocytes among others [21]. Initially, exosomes were suggested to play the role of
removing molecules unnecessary for cellular metabolism that were only partially degraded by the
lysosomal system [22]. However, as investigations progress, their functions appear to be considerably
more complex: platelets secrete coagulation-regulating exosomes [23], extracellular vesicles of cardiac
progenitors are capable of inhibiting cardiomyocyte apoptosis following myocardial infarction [24], and
astrocyte-derived exosomes decrease neuronal damage caused by hypoxia through in vivo autophagy
regulation [25].
It is clear from these observations that since exosomes carry particular profiles of proteins,
RNA, and microRNAS but recap the internal content of their source cells, these nanoparticles appear
to undergo a process of “selective packaging” as a way of refining and enhancing intercellular
communication at distant sites and thus regulating important biological functions [26]. Exosomes
are internalized by target cells through direct membrane fusion or endocytosis [27] and act mainly
by regulating the expression of specific proteins. These effects can be accomplished through the
direct transport of mRNAs to be translated or the delivery of microRNAs that lead to transcriptional
repression and consequent genetic silencing [28,29].
Importantly, exosomes as molecular messengers have the potential to modulate several
pathological scenarios, such as the maintenance of tumor microenvironments. This is accomplished
through different biological processes, mainly those involved in immune responses and that include,
for instance, signal transduction and antigen presentation [30–32]. In fact, there is growing evidence
about the modulation of immune cells functions by exosomes, which can be particularly observed
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in the case of tumor-derived exosomes. Tumor cells can secrete exosomes capable of attenuating the
responses of lymphocytes, macrophages, NK cells, and DCs, as well as promoting the expansion of
myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immature myeloid cells involved
in states of immunosuppression [29,33].
However, some studies, in contrast, have pointed to a possible role of exosomes in antitumor
immunovigilance as carriers of tumor antigens to be loaded into dendritic cells. Wolfers et al.
showed that exosomes derived from solid tumors such as colon and breast cancer, when delivered
to dendritic cells, lead to the activation of T-cell-mediated immune responses culminating in tumor
rejection. Interestingly, there was cross-protection among the various tumors evaluated, pointing to
the possibility that these exosomes carry common tumor antigens, which would be easily presented
by MHC-I molecules in dendritic cells [34]. A similar approach was tested using exosomes derived
from heat-stressed carcinoembryonic antigen (CEA) positive tumor cells. These particles induced DC
maturation that culminated in cytotoxic lymphocytic responses and reduced tumor burden [35].
In our laboratory, we initially speculated that exosomes purified from serum of patients with
hematologic malignancies could also be useful as an antigenic pulse in the development of new forms
of immunotherapy. This seemed promising considering previous results with solid cancers and the
fact that exosomes are released containing particular contents of proteins, RNAs, and microRNAs that
recap the internal content of the maternal cells, and could thus contain specific antigenic material for
the priming of dendritic cells. To evaluate this hypothesis, exosomes from serum of patients with
acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) were purified and used as an
antigenic source for DCs in co-cultures with lymphocytes and leukemic K562 cells. Surprisingly, our
results demonstrated that incubation of DCs with patients’ exosomes decreased the lysis of target cells,
probably corresponding to an immune tumor evasion mechanism in vivo [36].
In fact, because they are responsible for T lymphocyte activation, DCs also play an important role
in the sensitive balance between immune response and tolerance. Previous studies have shown that
mature DCs can limit effector T-cell responses and promote immune tolerance in response to different
signaling molecules such as IL-27 and IL-10 [37,38]. In the case of cancer patients, circulating exosomes
could possibly be generated in the tumor microenvironment, also containing immunosuppressive
molecules, constituting an effective mechanism for the paracrine induction of tolerance and therefore
tumor escape.
Our group also demonstrated that these DCs stimulated with exosomes from AML patients,
despite not altering lymphocyte proliferation rates, led to a marked decrease in INF-γ production by
these effector cells, and INF-γ levels were inversely related to CD86 expression in DCs. Therefore, we
can speculate that in AML, the exosome-induced suppression of cytotoxicity may, at least in part, be
the result of dysregulation in co-stimulatory molecules in DCs, such as CD86, leading to decreased
activation of lymphocytes with impaired INF-γ production [36].
Interestingly, a study with a murine model of AML had previously demonstrated the effectiveness
of using exosomes as a pulse of DCs [39]. One possible explanation for this discrepancy in relation
to human patients may be that the tumor in mice was not autologous, but tumor cells had been
injected into these animals. This approach may not necessarily mimic the systemic immunosuppressive
environment involved in AML in humans, which may explain why promising preclinical results have
not been reproduced in human trials.
Furthermore, our results are in line with the latest studies published on this topic, consolidating
the idea that exosomes participate in the induction of immunotolerance in AML. Hong et al. evaluated
AML patients treated with NK cell infusion and could observe the effect of patients’ exosomes present
in pretreatment samples. These authors noted that there was a decrease in the cytotoxicity of these NK
cells when they were incubated along with the serum containing exosomes that was extracted from
patients prior to treatment [40]. Moreover, specifically in relation to dendritic cells, a recent study with
prostate cancer patients demonstrated that after incubation of DCs with patients’ exosomes, there was
also a significant decrease in the release of inflammatory cytokines and less activation of INF-producing
Cells 2019, 8, 1648 5 of 12
CD8+ lymphocytes [41]. Recent studies have also demonstrated the immunosuppressive potential of
extracellular vesicles in gliomas [42], and melanoma-derived exosomes have been shown to inhibit the
differentiation of monocytic precursors in dendritic cells, leading to increased TGF-β production and
suppression of lymphocyte proliferation [43].
3.2. Possible Roles Uncovered for Micrornas and Epigenetics?
Epigenetics describes cellular modifications other than DNA sequence variations that can be
heritable and modified by environmental stimuli leading to changes in gene expression. These changes
arise due to processes such as DNA methylation, histone modifications, chromatin remodeling proteins,
miRNAs, and non-coding RNAs, and have the potential to modify the tumor microenvironment which
in turns can influence cancer initiation, proliferation, and metastasis [44–46].
DNA methylation is one of the best characterized epigenetic modifications. This process is
dynamically regulated through the action of DNA methyltransferases (DNMTs) and ten-eleven
translocation (TET) enzymes. DNMTs add methyl groups to certain regions of the genome that
contain clusters of CpG sequences (CpG islands); most of them are located upstream of promoters,
thus resulting in the silencing of certain genes [47]. In a transplant model, Zhu et al. demonstrated
that microvesicles derived from K562 leukemia cells contained BCR-ABL1 mRNA, which can be
transferred to mononuclear cells from the normal donor, resulting in the expression of a malignant
phenotype [48]. Genomic instability was the main mechanism observed in these cells, and this was
achieved by upregulation of methyltransferases and global DNA hypermethylation. Furthermore,
the treatment of microvesicles with RNase led to a decrease in DNMT3a and DNMT3b, proving that
leukemia-derived microvesicles influenced the methylation pattern of target cells via transmission of
microvesicular RNA. Thus, the microvesicular cargo derived from neoplastic cells may deliver enzymes
involved in methylation and/or demethylation to recipient cells, inducing changes in the expression of
tumor-related genes, which in turn leads to accelerated tumor proliferation and metastasis.
Chromatin structure is also crucial for gene expression regulation and may be modulated by
histone modifications [49]. However, the role of extracellular vesicles in posttranslational histones
modifications remains controversial. Sharma et al. used bioinformatic analysis and observed an
impressive overlap between genes relevant to transgenerational epigenetic inheritance and the cargo
of exosomes released by different cell types, including cancer cells. Among such genes were those
related to histone acetylation, deacetylation, ubiquitination, and other histone modifications, indicating
that exosomal mRNAs and proteins may directly or indirectly participate in the response to the
environmental exposure and epigenetic modification [50]. Importantly, we may speculate that
these changes in mononuclear cells may have some specific effects on dendritic cells, which should
undergo investigation.
MicroRNAs (miRNAs) are small noncoding RNAs (17–25 nucleotides long) that also control gene
expression by promoting degradation or repressing translation of target mRNAs. miRNAS are seen as
master regulators, efficiently tuning fundamental cellular processes such as proliferation, apoptosis,
and development [51]. The biosynthesis of miRNAs is a multistep process that starts in the nucleus
following transcription and continues to the cytoplasm, where the mature miRNA molecule exerts its
main functions [52].
Owing to their relatively small size, miRNAS are the most abundant RNAs in exosomes [53], and
novel functions for exosomal miRNAs are being revealed in the effectuation of immune responses.
For instance, miR-21 and miR-29a can act as ligands to toll-like receptors (TLR) in immune cells,
triggering a TLR-mediated prometastatic inflammatory response that ultimately leads to tumor growth
and metastasis [54]. Exosomes isolated from peripheral blood of systemic lupus erythematosus (SLE)
patients have recently been demonstrated to have the ability to stimulate the secretion of INF-α by
plasmocitoid dendritic cells (pDC), and the authors could show that this effect was related to the
microRNAs isolated from these exosomes. Interestingly, synthetic microRNAs containing an IFN
induction motif could also activate cytokine secretion and induce pDC maturation, revealing the
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possibility of manipulating exosomal microRNAs as a potential therapeutic target to be explored also
in neoplastic diseases [55].
In summary, extracellular vesicles released by tumoral cells into the microenvironment may
influence the phenotype of receptor cells, including their epigenetic status, through delivery of
mRNAs and miRNAs. Considering the lack of information on how these specific mechanisms may
impact dendritic cells and thus favor tumor proliferation, this remains an exciting field for future
scientific exploration.
4. Implications for Therapy
4.1. Tumor-derived Exosomes (TEX)
As afore-discussed, among the biological functions previously described for exosomes, we
can mention their properties as modulators of the immune system. Depending on their internal
content, these nanoparticles may potentiate the activation of CD4+ and CD8+ T lymphocytes [56],
and macrophage-derived exosomes are capable of transferring antigens to dendritic cells, thereby
increasing the response of CD4+ T cells [57].
Despite the quantitative and qualitative defects observed in the DCs of cancer patients, it is possible
to generate and differentiate mature dendritic cells from autologous peripheral blood mononuclear
leukocytes through specific culture media supplemented with proinflammatory cytokines [58].
The development and enhancement of these cell culture techniques led to increasing cell yields
throughout the 1990s, which allowed the exploration of the pulse of DCs with tumor antigens as a
new potential anticancer vaccines [59,60]. The most commonly used conventional protocols employ
peripheral blood mononuclear leukocytes that are differentiated ex vivo into monocytes and later on
into mature dendritic cells [61,62], which are then pulsed with specific tumor antigens in various forms,
such as synthetic peptides [63], tumor nucleic acid [64], and apoptotic bodies [65] among others.
The first study that tested dendritic cell vaccines in cancer patients was published in 1996 and
evaluated the use of tumor peptide-pulsed dendritic cells in four patients diagnosed with follicular
B-cell lymphoma. All patients developed detectable antitumor cell responses, and two of the patients
presented complete regression of the tumor after the vaccination schedule [66]. Since then, results from
both in vitro and in vivo experiments have conclusively demonstrated the safety of these vaccines
and their effectiveness in developing a specific immune response against various tumor types [67,68],
including hematologic malignancies [69,70].
Considering the ease of obtaining microvesicles from patients’ serum and the possibility of
their direct cellular transfection in co-cultures independent of artifacts such as viral vectors and
electroporation, several studies aimed to evaluate the use of these microvesicles as an antigenic pulse
for dendritic cells. Early animal studies showed that vaccination with DCs pulsed with exosomes
derived from leukemic cells resulted in longer survival compared with vaccination with DCs pulsed
with tumor lysates or the direct infusion of exosomes only [39,71].
However, as described earlier, these results are contradictory, since the stimulation with exosomes
led to immune tolerance of DCs in various types of tumors, such as AML and prostate cancer [36,41].
Therefore, another possibility to be considered is the use of exosomes secreted by dendritic cells
themselves after being stimulated with tumor antigens.
4.2. Exosomes from Dendritic Cells Pulsed with Tumor Antigens (Dendritic Cell Derived Exosomes–DEX)
The potential use of exosomes as autonomous carriers of therapeutic material is evident when
considering their cellular biological origin, allowing these nanoparticles to contain a deformable
membrane and cytoplasm-like internal content. This guarantees resistance to rupture during trafficking,
and the size allows diffusion even through small spaces such as blood capillary fenestrations, hence
the recent interest in engineering and manipulating these exosomes to contain antigenic material for
immune stimulation.
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However, a simpler, more natural approach with less manipulation involves the use of exosomes
secreted by DCs themselves after appropriate antigenic pulse. The rationale for this use comes
from the observation that, as DCs themselves, DC-derived exosomes (DEX) retain the expression of
important molecules involved in immune activation, such as functional MHC-peptide complexes and
co-stimulatory molecules. These particles would still have some advantages over the infusion of the
DCs themselves, such as their possible greater tissue dispersion and resistance to immunosuppressive
agents [72]. Furthermore, the production process of these vaccines would scarcely differ from the
conventional production of vaccines using dendritic cells, solely by adding a purification phase of
the nanoparticles from the culture medium, but with the advantage that this acellular material can
probably be stored for longer periods.
Initial studies in animal models have shown that exosomes purified from a culture medium in
which DCs were pulsed with tumor peptides were capable of triggering potent immune responses
leading to tumor regression in murine breast cancer [73]. Exosomes derived from DCs expressing
alpha-feto-protein also led to significant antigen-specific responses in hepatocellular carcinoma mainly
through remodeling of the tumor microenvironment and immune activation of CD8+ lymphocytes [74].
Despite phase-I clinical trials having confirmed the safety of DEX administration and the feasibility
of a clinical scale production, the results in terms of clinical efficacy and specific immune response
elicitation have been modest. The first two clinical trials used autologous DCs loaded with peptides
of melanoma-associated antigen (MAGE) in advanced lung cancer and melanoma. In the case of
lung cancer patients, only one of five patients showed increased T-cell activation evidenced by the
enzyme-linked immunospot (ELISPOT) assay [75]. In the case of melanoma, the vaccination schedule
led to two patients to achieve disease stability, one minor and one partial response, with some of these
patients presenting with progressive disease prior to vaccination. However, as in the other study, no
evidence of T-cell response was identified in patients’ peripheral blood [76].
Interestingly, despite this low capacity for lymphocyte activation, these DEX demonstrated the
expression of killer cell lectin–like receptor subfamily K member 1 ligands (NKG2D-L) and this fact
was probably responsible for the stimulation and activation of NK cells through their NKG2D receptor.
In fact, there was an increase in NK cells in peripheral blood and their cytotoxicity was considerably
enhanced after treatment [77].
A second generation of DEX vaccines was tested by using IFN-γ to mature DCs, which led
to increased expression of co-stimulatory molecules [78]. In the case of lung cancer patients, these
IFN-γ-stimulated DCs once again failed to reveal evidence of specific T cell immune responses; however,
they stimulated NK cell activation, which correlated with longer progression-free survival [79].
Despite these so far poor results, the mentioned studies have demonstrated the effect of dendritic
cell-derived exosomes on the lytic functions of NK cells, and the evolution of these preparations toward
greater immunogenicity is hoped to lead to more effective and lasting clinical responses. More details
of these techniques and clinical trials are reviewed in the paper by Pitt et al. [72].
4.3. Engineering More Immunogenic Nanoparticles for Immunotherapy
Another interesting approach to increase the anti-tumor effect of dendritic cells involves the
encapsulation of antigenic material within the exosomes. So far, there has been demonstration of
effective internalization of siRNA and RNA in nanoparticles through their electroporation, as well as the
possibility of using these nanoparticles as drug carriers, as already demonstrated with doxorubicin [80].
This approach is yet to be tested as a possible tool for inducing expression of tumor-specific antigens
within the exosomes so that this material could then be transferred to DCs.
To further improve the immunogenicity of exosomes but in the opposite direction, in 2017,
Huang et al. manipulated leukemic cell-derived exosomes to silence TGF-1 expression. With this
approach, the pulse of DCs with this material induced a more potent anti-tumor immune response than
did non-manipulated exosomes, pointing again to the fact that neoplastic cell-derived exosomes may
contain molecules with immunosuppressive capacity that impair their use as an antigenic pulse. Thus,
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current evidence suggests that exosomes should go through editing processes for a proper anti-tumor
immune response [81]. In this sense, another option would be to manipulate these nanoparticles to
induce specific protein content. For instance, Segura et al. demonstrated that exosomes derived from
mature DCs are able to trigger effective T-cell responses mainly through transfer of MHC class II and
intercellular adhesion molecule 1 (ICAM-1) [82]. These findings corroborate the idea that changes in
exosome protein composition may alter the immune activation capabilities of exosomes; consequently,
editing this content may improve their performance.
Another possible approach is the insertion of specific microRNAs into dendritic cells for
enhanced immunogenicity. For instance, exogenous miRNA-155 could be successfully inserted
into tumor-cell-derived exosomes and led to increased levels of MHCII and co-stimulatory molecules
such as CD83 and CD86 on dendritic cells’ surface after exosomal delivery. This also led to enhanced
production of INF-γ and IL-10, demonstrating the possible use of exosomal microRNAs as a maturation
stimulus for DCs [83].
5. Conclusions and Future Perspectives
The discovery of interactions between tumor cells and the immune system through nanoparticle
trafficking has revealed an important factor in the establishment of malignant characteristics such as
invasion, angiogenesis induction, and metastasis. Similarly, the purification and manipulation of these
nanoparticles open the prospect of a new class of therapeutic tools that can be of great value in treating
patients with different types of tumors, using the immune system in a more personalized and possibly
less toxic manner. This is a new field of study with exciting possibilities; thus, the development of
projects to unravel the biology of these interactions and the implementation of clinical trials should be
strongly encouraged.
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